Capricor's Duchenne cell therapy gets PDUFA date extended as FDA reviews new data

statnews.com·Aug 20, 2026 · 5 g fa

Capricor Therapeutics' Duchenne treatment is heading for an FDA rejection

benzinga.com·Aug 24, 2026 · 1 g fa

Why Is Capricor Therapeutics Stock Trading Higher on Monday? - Capricor Therapeutics (NASDAQ:CAPR)

statnews.com·Aug 20, 2026 · 5 g fa

Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study

biopharmadive.com·Aug 24, 2026 · 2 g fa

FDA extends review of Capricor cell therapy; Pain drug startup to go public

morningstar.com·Aug 20, 2026 · 5 g fa

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit